Retatrutide: Weight Loss, Dosing, Side Effects 2026

ExcelMale Consensus

Retatrutide has produced some of the largest average weight reductions reported in a Phase 3 obesity program, reaching 28.3% at 80 weeks and 30.3% at 104 weeks in a severe-obesity extension. The drug still has no FDA approval, no approved dosing instructions, and no proven cardiovascular outcome benefit.

For men interested in retatrutide, the important question is no longer whether the drug produces major weight loss. The key issues are how much dose is needed, how well side effects are tolerated, and how lean mass is protected during large reductions in body weight.

Key Takeaways

• Retatrutide activates GIP, GLP-1, and glucagon receptors.
• TRIUMPH-1 reported 28.3% average weight loss with 12 mg at 80 weeks.
• A TRIUMPH-1 extension reported 30.3% average weight loss at 104 weeks.
• The lower 4 mg dose produced 19.0% average weight loss with fewer adverse-event discontinuations.
• TRIUMPH-2 reported up to 20.8% average weight loss in people with type 2 diabetes.
• Benefits were also reported for HbA1c, waist circumference, triglycerides, blood pressure, sleep apnea, knee pain, and liver fat.
• Retatrutide reduces both fat mass and lean mass. Available DXA evidence does not show disproportionate lean-mass loss compared with other major obesity treatments.
• No clinical trial has established a special benefit from combining retatrutide with TRT.
• Dysesthesia, including abnormal skin sensitivity, tingling, burning, or numbness, has appeared repeatedly across Phase 3 studies.
• Retatrutide is still investigational. FDA states retatrutide is not eligible for compounding under federal law.
• Lilly plans a U.S. regulatory submission in the first quarter of 2027.

Retatrutide entered 2026 with impressive Phase 2 data. Five positive Phase 3 studies have since changed the discussion.

The strongest obesity trial reported 70.3 pounds of average weight loss with 12 mg over 80 weeks. A two-year extension involving people who started with a BMI of at least 35 reported an average loss of 85 pounds.

Those numbers deserve attention. They also need context because higher doses produced more gastrointestinal symptoms, dysesthesia, and treatment discontinuation.

What is retatrutide and how does it work?​

Retatrutide is an investigational once-weekly peptide that activates GIP, GLP-1, and glucagon receptors in a single molecule.

Retatrutide was previously identified as LY3437943.

GLP-1 signaling affects appetite, satiety, gastric emptying, and glucose-dependent insulin secretion. GIP contributes to insulin secretion and metabolic regulation. Glucagon receptor activity influences hepatic metabolism, lipid metabolism, and energy expenditure.

The glucagon component separates retatrutide from semaglutide and tirzepatide.

Medication	GLP-1	GIP	Glucagon
Semaglutide	Yes	No	No
Tirzepatide	Yes	Yes	No
Retatrutide	Yes	Yes	Yes

The term "GLP-3" sometimes appears in online discussions. GLP-3 is not a scientific drug class. Lilly describes retatrutide as a triple hormone receptor agonist.

Retatrutide has a half-life of roughly six days, supporting the once-weekly schedule studied in clinical trials.

How much weight loss did retatrutide produce in Phase 3 trials?​

Retatrutide produced average weight reductions ranging from 12.7% to 28.7% across the major Phase 3 obesity populations reported so far.

Trial	Population	Duration	Highest Reported Average Weight Loss
TRIUMPH-1	Obesity or overweight without diabetes	80 weeks	28.3% with 12 mg
TRIUMPH-1 extension	Starting BMI of at least 35	104 weeks	30.3% with 12 mg
TRIUMPH-4	Obesity or overweight with knee osteoarthritis	68 weeks	28.7% with 12 mg
TRIUMPH-2	Obesity or overweight with type 2 diabetes	80 weeks	20.8% with 12 mg
TRIUMPH-3	Severe obesity with established cardiovascular disease	80 weeks	22.6% with 12 mg

TRIUMPH-1 provides the clearest dose-response comparison.

At 80 weeks:

• 4 mg: 19.0% average weight loss, or 47.2 pounds.
• 9 mg: 25.9%, or 64.4 pounds.
• 12 mg: 28.3%, or 70.3 pounds.
• Placebo: 2.2%, or 5.5 pounds.

Among participants receiving 12 mg, 62.5% lost at least 25% of their initial weight.

45.3% lost at least 30%.

27.2% lost at least 35%.

One-third reached a BMI below 25.

Why does the statistical method used in TRIUMPH-1 matter?​

The reported percentage depends partly on how investigators handle treatment interruptions and discontinuations.

The 28.3% headline result uses an efficacy estimand, which estimates outcomes under the planned treatment strategy.

The treatment-regimen analysis produced a 25.0% average reduction with 12 mg.

Both numbers are useful. The 25.0% estimate incorporates more treatment interruptions and discontinuations encountered during the trial.

What health effects occurred beyond retatrutide weight loss?​

Retatrutide produced substantial improvements across several obesity-related metabolic and physical complications.

In TRIUMPH-1, reported changes included:

• Triglycerides decreased by as much as 41.0%.
• Non-HDL cholesterol decreased by as much as 24.2%.
• Systolic blood pressure decreased by as much as 12.3 mmHg.
• Waist circumference decreased by as much as 9.5 inches.

TRIUMPH-1 also included people with moderate-to-severe obstructive sleep apnea.

The apnea-hypopnea index fell by as much as 36.1 events per hour from a baseline of 58.6 events per hour.

This represents a 60.6% reduction.

TRIUMPH-4 studied people with obesity or overweight plus knee osteoarthritis. WOMAC knee-pain reductions approached 75% in the retatrutide groups.

TRANSCEND-T2D-1 provided the first peer-reviewed Phase 3 retatrutide diabetes results. HbA1c fell by as much as 2.0 percentage points after 40 weeks.

Up to 90% reached an HbA1c below 7%.

46% reached an HbA1c below 5.7%.

What happened to liver fat with retatrutide?​

Retatrutide produced large reductions in liver fat in a randomized Phase 2a MASLD substudy.

At 24 weeks, average relative liver-fat reductions were:

• 1 mg: 42.9%.
• 4 mg: 57.0%.
• 8 mg: 81.4%.
• 12 mg: 82.4%.
• Placebo: a 0.3% increase.

At week 24, 86% of participants receiving 12 mg reached liver fat below 5%.

Later imaging showed further improvement, but the week-48 imaging sample was substantially smaller. The later percentage deserves more caution.

Does retatrutide reduce heart attacks or strokes?​

No definitive cardiovascular outcome benefit has been established.

TRIUMPH-3 included exploratory cardiovascular analyses.

For MACE-5, 44 events occurred in the pooled retatrutide groups and 52 occurred with placebo.

The hazard ratio was 0.82, with a 95% confidence interval of 0.55 to 1.22.

For MACE-3, 27 events occurred with retatrutide and 23 with placebo.

The hazard ratio was 1.12, with a 95% confidence interval of 0.64 to 1.96.

Both confidence intervals include 1.0.

Retatrutide improved several cardiovascular risk markers, but improved risk markers do not prove fewer heart attacks, strokes, or cardiovascular deaths.

Larger cardiovascular and renal outcome trials are designed to answer this question.

What happens to muscle and lean mass during retatrutide treatment?​

Retatrutide reduces both fat mass and lean mass during substantial weight loss.

A 2025 DXA substudy in people with type 2 diabetes reported reductions of up to 26.1% in total fat mass. Exploratory analyses found losses of up to 10.9 kg of total fat mass and up to 6.5 kg of lean mass.

The proportion of lean mass lost relative to total weight loss was similar to proportions reported with other major obesity treatments.

This distinction matters because DXA lean mass is not identical to skeletal muscle. Lean mass includes muscle, organs, connective tissue, glycogen, and body water.

Large reductions in body weight still create a practical muscle-preservation problem, especially for older adults and people starting with low muscle mass.

Useful priorities include:

• Progressive resistance training.
• Adequate protein intake.
• Avoiding unnecessarily severe calorie restriction.
• Monitoring strength and physical performance.
• Using body-composition testing when clinically useful.

For a broader discussion, see ExcelMale's guide to preventing muscle loss during GLP-1 treatment.

Does TRT prevent muscle loss during retatrutide treatment?​

No clinical trial has shown that TRT prevents retatrutide-associated lean-mass loss.

There are also no randomized studies designed specifically around men receiving testosterone replacement therapy and retatrutide.

Major fat loss might alter insulin sensitivity, blood pressure, sleep apnea severity, lipid levels, SHBG, estradiol production, caloric requirements, and medication needs. A man losing 40 to 80 pounds might therefore find that parts of his broader TRT management require reassessment.

TRT should not replace adequate nutrition or resistance exercise.

Which retatrutide side effects appear most often?​

Gastrointestinal symptoms remain the most frequent adverse effects reported with retatrutide.

In TRIUMPH-1, the 12 mg group reported:

• Nausea: 42.4%.
• Diarrhea: 32.0%.
• Constipation: 26.1%.
• Vomiting: 25.3%.

Adverse-event discontinuation increased with dose:

• 4 mg: 4.1%.
• 9 mg: 6.9%.
• 12 mg: 11.3%.
• Placebo: 4.9%.

The 4 mg result deserves more attention than it often receives.

Average weight loss reached 19.0%, while adverse-event discontinuation remained slightly below placebo.

What is dysesthesia and why does retatrutide cause concern about it?​

Dysesthesia is an abnormal sensory experience involving symptoms such as tingling, burning, numbness, skin hypersensitivity, or unusual sensitivity to touch.

The effect has appeared repeatedly in Phase 3 retatrutide trials.

TRIUMPH-1 reported dysesthesia in:

• 5.1% with 4 mg.
• 12.3% with 9 mg.
• 12.5% with 12 mg.
• 0.9% with placebo.

TRIUMPH-4 reported a higher 20.9% rate with 12 mg.

Later Phase 3 trials reported lower rates, including 7.3% with 12 mg in TRIUMPH-2 and 6.4% in TRIUMPH-3.

Most reported cases were mild to moderate, and most resolved during treatment.

The mechanism is still uncertain.

What retatrutide dosing schedules were used in Phase 3 trials?​

The Phase 3 program generally started retatrutide at 2 mg once weekly and increased the dose every four weeks.

Target Dose	Trial Escalation
4 mg	2 mg, then 4 mg
9 mg	2 mg, 4 mg, 6 mg, then 9 mg
12 mg	2 mg, 4 mg, 6 mg, 9 mg, then 12 mg

These are clinical-trial schedules, not prescribing instructions.

Retatrutide has no FDA-approved dose.

Online protocols involving 0.25 mg, 0.5 mg, split injections, twice-weekly use, microdosing, or peptide combinations were not established by the Phase 3 retatrutide program.

Is the highest retatrutide dose always the best dose?​

No. TRIUMPH-1 shows a clear tradeoff between additional weight loss and additional adverse effects.

The 4 mg dose produced 19.0% average weight loss after only one escalation step.

The 12 mg dose produced 28.3%.

Higher doses also produced more nausea, vomiting, dysesthesia, and treatment discontinuation.

If retatrutide receives regulatory approval, dose selection will need to balance weight-loss goals, medical conditions, side effects, response, and individual tolerance.

More drug does not automatically mean a better clinical outcome.

Is retatrutide FDA approved or legally compounded in the United States?​

No. Retatrutide remains an investigational drug as of September 2, 2026.

Lilly states that retatrutide has not received approval from any regulatory agency.

FDA also states that retatrutide is not eligible for compounding under federal law.

Anything sold outside a Lilly-sponsored clinical trial does not represent an FDA-approved retatrutide product with verified manufacturing, purity, potency, sterility, or labeling.

FDA has taken enforcement action against sellers marketing products labeled as retatrutide.

Lilly announced on July 23, 2026 that a U.S. Biologics License Application submission is planned for the first quarter of 2027.

A regulatory submission is not an approval.

No confirmed U.S. launch date exists, and no official commercial price has been announced.

What are ExcelMale members reporting about retatrutide?​

ExcelMale members report substantial variation in appetite suppression, weight loss, gastrointestinal tolerability, fatigue, sleep, food preferences, alcohol cravings, libido, and sensory symptoms.

Several members describe experiences that differ from semaglutide or tirzepatide. Others report dose-response problems or side effects that caused them to stop treatment.

These reports are useful for identifying questions worth studying, but they do not establish efficacy rates, safety rates, dosing instructions, sterility, product purity, or drug combinations.

This distinction is especially important because members using products outside Lilly trials do not have access to an FDA-approved retatrutide product.

Read ExcelMale Member Experiences with Retatrutide for community reports separated from clinical-trial evidence.

What questions do readers ask most about retatrutide?​

Is retatrutide a GLP-3 drug?​

No. GLP-3 is an inaccurate internet nickname. Retatrutide activates GIP, GLP-1, and glucagon receptors.

How much weight did people lose with retatrutide?​

The 12 mg group in TRIUMPH-1 lost an average of 28.3% at 80 weeks. Participants with a starting BMI of at least 35 who entered the extension reached 30.3% average weight loss at 104 weeks.

Does retatrutide preserve muscle?​

Retatrutide reduces fat mass and lean mass. Current DXA evidence suggests the proportion of lean-mass loss is similar to other major obesity interventions rather than disproportionately high.

Does TRT prevent muscle loss from retatrutide?​

No clinical trial has demonstrated that TRT prevents retatrutide-associated lean-mass loss.

Is retatrutide better than tirzepatide or semaglutide?​

No Phase 3 head-to-head obesity trial has established superiority over tirzepatide or semaglutide.

Separate trials differ in study populations, duration, diabetes status, adherence, discontinuation rates, lifestyle programs, and statistical methods. Cross-trial percentages do not provide a clean head-to-head comparison.

What retatrutide doses were studied?​

The Phase 3 obesity program studied maintenance targets of 4 mg, 9 mg, and 12 mg. Participants generally began at 2 mg weekly and escalated every four weeks according to the trial protocol.

Is the Phase 3 dosing schedule an approved retatrutide protocol?​

No. These doses describe clinical research protocols. Retatrutide has no FDA-approved dosing instructions.

Is compounded retatrutide legal in the United States?​

FDA states that retatrutide is not eligible for compounding under federal law.

When is retatrutide expected to reach the FDA?​

Lilly plans to submit retatrutide for U.S. regulatory review in the first quarter of 2027. No approval date or commercial launch date has been confirmed.

Which ExcelMale discussions add useful real-world context?​

• Retatrutide Peptide: Dosing, 28% Weight Loss and Side Effects
• ExcelMale Member Experiences with Retatrutide
• Looking for Retatrutide Experiences
• The Ultimate GLP-1 Guide: Weight Loss, Side Effects and Sarcopenia Risk
• GLP-1 Medications: Preventing Muscle Loss During Treatment
• ExcelMale Weight Loss Options Forum

What matters most as retatrutide moves toward FDA review?​

The next important retatrutide question is less about maximum weight loss and more about the lowest dose that delivers enough weight loss with acceptable long-term tolerability.

TRIUMPH-1 makes this issue hard to ignore. The 4 mg dose produced 19.0% average weight loss while adverse-event discontinuation was 4.1%. The 12 mg dose increased average weight loss to 28.3%, but discontinuation rose to 11.3%.

For some patients, another nine percentage points of weight loss might justify the additional exposure and side effects. For others, a lower maintenance dose might produce a better clinical balance.

Regulatory approval will answer only part of the retatrutide story. Long-term practice will need to determine how physicians balance weight loss, metabolic improvement, muscle preservation, side effects, cost, and maintenance dosing over years rather than months.

Which sources support this retatrutide guide?​

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389:514-526. doi:10.1056/NEJMoa2301972

2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023;402:529-544. doi:10.1016/S0140-6736(23)01053-X

3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine. 2024;30:2037-2048. doi:10.1038/s41591-024-03018-2

4. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2025;13:674-684. doi:10.1016/S2213-8587(25)00092-0

5. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide in people with type 2 diabetes, TRANSCEND-T2D-1. The Lancet. 2026;407:2402-2413. doi:10.1016/S0140-6736(26)00967-0

6. Eli Lilly and Company. TRIUMPH-4 Phase 3 results. December 11, 2025. TRIUMPH-4 Phase 3 results

7. Eli Lilly and Company. TRIUMPH-1 Phase 3 results. May 21, 2026. TRIUMPH-1 Phase 3 results

8. Eli Lilly and Company. TRIUMPH-1, obstructive sleep apnea, knee osteoarthritis, and TRANSCEND-T2D-1 results. June 6, 2026. Additional Phase 3 results

9. Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 Phase 3 results. July 23, 2026. TRIUMPH-2 and TRIUMPH-3 results

10. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated 2026. FDA information on unapproved GLP-1 drugs and retatrutide

Medical Disclaimer

This article is for educational purposes and does not provide individual medical advice.

Retatrutide remains investigational and has not received FDA approval or approval from another regulatory agency as of September 2, 2026. No FDA-approved retatrutide product, prescribing information, dosing schedule, or commercial formulation exists.

Clinical-trial doses discussed in this article document research protocols. They are not instructions for self-treatment.

Anyone seeking treatment for obesity, diabetes, sleep apnea, metabolic disease, or weight-related complications should work with a qualified healthcare professional using approved therapies and appropriate medical monitoring.

Who wrote this article?​

Nelson Vergel is the founder of ExcelMale.com and an author and men's health advocate focused on testosterone replacement therapy, hormone health, sexual health, metabolic health, and healthy aging.

He is the author of Testosterone: A Man's Guide, Beyond Testosterone, The hCG Advantage, and The Peptide Consensus.

Updated September 2, 2026.

What is ExcelMale?​

ExcelMale.com is a men's health community with more than 24,000 members and over 20 years of archived discussions covering testosterone replacement therapy, hormones, sexual health, weight management, peptides, laboratory testing, exercise, nutrition, and healthy aging.

The forum combines published medical evidence with moderated community discussions and long-term patient experience.

 

What are your goals with the Reta?

To see my abs again... it's been a minute.

 

Being a major horn dog myself, I wholeheartedly concur with your sentiments But it's mild in my case, just harder to finish for the most part. Some may find it more bothersome as it's likely different based on personal chemistry. Also, I take Selegeline which does help.

I understand I guess if it was really bad you would have stopped

 

To see my abs again... it's been a minute.

Well I asked because you mentioned that you are still drinking wine. You probably know this, and I don't want to sound like an ass, but the Reta is not magic. It will help you do the right thing but it won't do it for you. Alcohol is the worst thing you can consume if you're trying to drop fat. And you still need your diet - calories and macros, especially protein - on point.

So if you want abs you'll need to get to at most 15% body fat for a start and if you want solid abs, well thats going to require you to be 10% to 12%. Of course it depends upon how you carry your fat, but those numbers are typical.

Now if you just want to get rid of the Dad bod and get below maybe 18%, yeah you can cheat a bit, but its not ideal.

And I do love my red wine!

 

Well I asked because you mentioned that you are still drinking wine. You probably know this, and I don't want to sound like an ass, but the Reta is not magic. It will help you do the right thing but it won't do it for you. Alcohol is the worst thing you can consume if you're trying to drop fat. And you still need your diet - calories and macros, especially protein - on point.

So if you want abs you'll need to get to at most 15% body fat for a start and if you want solid abs, well thats going to require you to be 10% to 12%. Of course it depends upon how you carry your fat, but those numbers are typical.

Now if you just want to get rid of the Dad bod and get below maybe 18%, yeah you can cheat a bit, but its not ideal.

And I do love my red wine!

You don't sound like an ass, that is excellent advice. In my case however, it doesn't apply. I am a lifelong gym rat and fitness enthusiast. At 68, I can say I have never had anything close to a Dad Bod.

I have a stressful job at times that involves a lot of long-distance driving and long hours. I had a six month stretch where I was constantly on the go and ended up accumulating some weight. My wife is on Reta, so I tried it.

Wine is one of life's pleasures that I will never give up. As for the abs, the top two are popping pretty good right now, it's the other six I'm after...

 

Oh! Well in that case, you clearly know what you're doing so... Carry on!

 

sourcing info: Retatrutide - A Game Changer in Obesity Pharmacotherapy - Page 2 - Excel Male Health Forum

 

Latest info: Retatrutide: The Next Generation Triple Agonist Transforming Weight Management - Excel Male Health Forum

 

Join our community for research purposes and share your experiences and transformations

 

Just an update:

I have maintained the 4 mg per week dosage for 3 1/2 months now. The fat loss has been dramatic, I am at 18% bodyfat right now and it's been a minute since I was this lean. Yes, there is some muscle loss as well, I would estimate about 10-15%, but I suppose that has to be expected with such rapid weight loss. I am now down to 205 lbs. I feel absolutely fantastic. I have lost a lot of visceral fat which you can't see, but you feel it. I just feel lighter and more energetic. Retatrutide is also very good for liver rejuvenation.

Nutrition is key, you really lose your appetite on these drugs. I tried keeping my protein intake up with food, but I wasn't eating enough. I started using more protein powder about halfway in and that helped a lot. I also increased my fiber intake as well.

There are some downsides... Definitely some malaise off and on, usually the day or two after injection. Libido is also less on those days. There is a disruption of dopamine in the gut, and it is noticeable. Appetite is greatly diminished which really needs to be monitored to ensure you are still getting enough nutrition.

I started a few other things around the same time; NAD+, Testogen and Prostamax, so those elements have also been a factor.

I would say without hesitation that this is one of the most effective substances I have ever taken.

 

Thanks for the input on your experiences.

Have you considered using oxandrolone or nandrolone to counter muscle loss ?

 

Thanks for the input on your experiences.

Have you considered using oxandrolone or nandrolone to counter muscle loss ?

I have never tried either of them, I’ll look in to it though as I plan on this being a full time part of my protocol. I am going to lower the dosage back down to 2 mg as a maintenance dose.

 

Thanks for the input on your experiences.

Have you considered using oxandrolone or nandrolone to counter muscle loss ?

@nelsonvergel

Which do you recommend? Also, what dosage and how long of a cycle? And finally... best source?

 

The glucagon receptor activation is the part that really stands out to me. GLP-1 drugs already help with appetite, but adding glucagon could increase energy expenditure and fat mobilization, which might explain the stronger fat loss results seen in trials.


I’m curious though, for guys on TRT who lift regularly, do you think this could affect muscle retention compared to the earlier GLP-1 medications?

 

I've decided to source some retatrutide from a Chinese supplier via platforms like Made-in-China or Alibaba, and I’m planning to order 10 x 10mg vials strictly for personal use. I'm currently on 10mg trizepitide from eli lilly and have been doing extensive research around it.


My plan is to send one vial to Janoshik for testing, provided all vials are from the same batch. Assuming the quality checks out, I intend to follow this dosing protocol:

• Week 1: 0.25mg twice per week
• Week 2: 0.25mg twice per week
• Week 3: 0.50mg twice per week
• Week 4: 0.50mg twice per week
• Week 5: 0.50mg twice per week
• Week 6: 0.50mg twice per week
  ...and so on.

From what I’ve read, a reconstituted 10mg vial only remains stable for about 28–35 days when refrigerated. Based on available information, it seems you can pre-load insulin syringes and freeze them — then thaw them in the fridge a day before use — but opinions are mixed.


Given that I’m relatively new to this, here are the concerns I currently have:

1. Is Janoshik the most reliable peptide testing service in the EU, and what is their typical turnaround time?
2. Is it safe to freeze retatrutide in preloaded insulin syringes? Some peptides degrade when frozen — does this apply to retatrutide?
3. How can I ensure sterile technique? I want to avoid contamination during reconstitution and dosing.
4. How do I verify the accuracy of micro-doses in insulin syringes? With such small doses, slight errors can matter.
5. What signs of degradation should I watch for in reconstituted or frozen peptides?
6. How should I store unopened lyophilized vials? Is room temperature okay, or should they be kept refrigerated?

How did it go?

Was the reta from you supplier good?

Any reference for acquiring in your Source ?

 

Thread 'Retatrutide: Real-World Community Experiences'

Apr 8, 2026

Dosing Protocols, Results, Side Effects & Sourcing — As Reported by Members of ExcelMale.com, LessWrong, and Reddit Peptide Communities
Compiled by Nelson Vergel | ExcelMale.com | April 2026

New to retatrutide? Start with the complete dosing, results & side-effects guide.

Important Disclaimer • Retatrutide (LY3437943) is an investigational compound by Eli Lilly. It is NOT FDA-approved as of April 2026. • All member accounts below reflect self-experimentation with research peptide...

• Nelson Vergel
• looking for retatrutide reviews retatrutide experiences who has used retatrutide
• Replies: 8
• Forum: Weight Loss Options

• 

 

Thread 'Retatrutide for Beginners: Starting Guide & Titration'

Mar 27, 2026

New to retatrutide? This beginner guide covers starting doses, how to titrate, safely, what results to expect, and how to avoid common side effects.

Looking for the full protocol? See the complete dosing, results & side-effects guide.

Curated By Nelson Vergel | ExcelMale.com | Updated March 2026

Key Takeaways Retatrutide is a first-in-class triple hormone receptor agonist (GLP-1 + GIP + glucagon) from Eli Lilly, currently in Phase 3 clinical trials under the TRIUMPH program. In Phase 3 (TRIUMPH-4), participants on the...

• Nelson Vergel
• retatrutide retatrutide versus mounjaro wegovy retratrutide dose retratrutide weight loss retrospective study
• Replies: 2
• Forum: Weight Loss Options

• 

 

Retatrutide is the triple-agonist GLP-1/GIP/glucagon peptide outperforming Ozempic and Mounjaro in trials. Complete dosing, results, and safety guide for men.

Could a single weekly injection deliver unprecedented weight loss while preserving muscle mass and improving cardiovascular health? For men on testosterone replacement therapy (TRT) struggling with stubborn body fat despite optimized hormone levels, this question has taken on profound significance. Retatrutide, a groundbreaking triple hormone receptor agonist, is reshaping our understanding of metabolic pharmacotherapy and offering hope where previous GLP-1 medications have fallen short.

The December 2024 release of Phase 3 TRIUMPH-4 trial results marked a watershed moment in obesity medicine: participants on the highest dose achieved an average weight loss of 28.7% over 68 weeks—the most substantial efficacy demonstrated in any obesity trial to date. Beyond the numbers, retatrutide addresses a critical concern for TRT patients: the quality of weight loss. While traditional GLP-1 medications have shown impressive weight reduction, concerns about muscle loss have tempered enthusiasm among men focused on body composition optimization.

View attachment 54755

This comprehensive guide examines retatrutide's unique triple agonist mechanism, clinical trial results, body composition effects, side effect profile, and practical considerations for men on TRT. Drawing from the latest peer-reviewed research and real-world experiences from the ExcelMale community, we'll explore whether this medication represents a genuine breakthrough or merely incremental progress in metabolic therapy.

Understanding Retatrutide's Triple Agonist Mechanism​

Retatrutide distinguishes itself from earlier incretin-based therapies through its unprecedented activation of three distinct hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple agonist approach represents a paradigm shift from the dual agonism of tirzepatide (Mounjaro/Zepbound) and single-receptor activation of semaglutide (Wegovy/Ozempic).

The Three Pillars of Metabolic Action​

GLP-1 Receptor Activation: The GLP-1 component slows gastric emptying, reduces appetite through central nervous system effects, and enhances glucose-dependent insulin secretion. For men on TRT, this translates to improved satiety without the hypoglycemic episodes that can occur with insulin or sulfonylurea medications.

GIP Receptor Activation: GIP activation contributes to insulin secretion in a glucose-dependent manner and appears to modulate fat metabolism. Importantly, GIP agonism may reduce the nausea commonly associated with pure GLP-1 receptor agonists—a significant advantage reported by ExcelMale community members who struggled with earlier medications.

Glucagon Receptor Activation: The addition of glucagon receptor agonism represents retatrutide's most innovative feature. Glucagon promotes hepatic gluconeogenesis and glycogenolysis, increases lipolysis in adipose tissue, and may enhance energy expenditure through thermogenesis. This mechanism directly targets visceral fat—the metabolically harmful abdominal adiposity that often persists despite TRT optimization.

The molecular structure of retatrutide demonstrates higher potency at the GIP receptor (EC50: 0.0643 nM) compared to GLP-1 (EC50: 0.775 nM) and glucagon (EC50: 5.79 nM) receptors. This preferential GIP activation, combined with balanced engagement of all three pathways, creates a pharmacological profile distinct from any existing obesity medication. With a half-life of approximately six days, retatrutide maintains therapeutic levels throughout a once-weekly dosing interval.

Clinical Trial Results: Unprecedented Weight Loss With Cardiovascular Benefits​

The Phase 3 TRIUMPH-4 trial, published in December 2024, evaluated retatrutide's efficacy in 445 adults with obesity or overweight plus knee osteoarthritis. The results exceeded even the most optimistic projections from financial analysts tracking the obesity medication market.

Weight Loss Efficacy​

At 68 weeks, participants who remained on the 12 mg dose achieved 28.7% average weight loss from baseline, equivalent to approximately 71 pounds for someone starting at 248.5 pounds. The 9 mg dose produced 26.4% weight loss, or about 64 pounds. When including participants who discontinued treatment (intention-to-treat analysis), the 12 mg dose still delivered 23.7% weight reduction—substantially exceeding the 20.2% achieved by tirzepatide at 72 weeks and the 14.9% demonstrated by semaglutide at similar durations.

These results take on additional significance when examining dose-response relationships. More than 90% of participants receiving the 12 mg dose achieved at least 10% weight loss, approximately two-thirds lost 20% or more, nearly half reached 25% reduction, and one quarter exceeded 30% weight loss. Such profound efficacy approaches outcomes previously associated only with bariatric surgery.

Cardiovascular and Metabolic Improvements​

Beyond weight loss, retatrutide produced marked improvements in cardiometabolic parameters—outcomes particularly relevant for men on TRT who may already carry elevated cardiovascular risk profiles. Systolic blood pressure decreased significantly, with approximately 40% of participants able to discontinue at least one antihypertensive medication. Non-HDL cholesterol levels dropped by roughly 20%, likely reflecting glucagon agonism's effect on hepatic PCSK9 degradation.

Glycemic control improved substantially across all dosing groups. Among participants with prediabetes at baseline, 72% reverted to normoglycemia during treatment. HbA1c reductions ranged from 0.43% at the lowest dose to 2.02% at the highest dose—clinically meaningful improvements that can substantially reduce microvascular and macrovascular complication risks.

Waist circumference—a proxy for visceral adiposity—decreased significantly, suggesting preferential loss of the metabolically harmful intra-abdominal fat that contributes to insulin resistance and cardiovascular disease. This visceral fat reduction holds particular importance for men on TRT, as testosterone therapy itself can reduce visceral adiposity but may plateau at higher body fat percentages.

Body Composition Effects: Addressing the Muscle Loss Concern​

For men on TRT committed to maintaining or building muscle mass, the body composition impact of any weight loss intervention demands scrutiny. The concern about lean mass loss with GLP-1 medications has been substantial, with some studies suggesting 25-40% of total weight loss comes from lean tissue.

The Fat-to-Lean Loss Ratio​

A June 2025 body composition substudy of retatrutide in people with type 2 diabetes provided reassuring data. Using dual-energy X-ray absorptiometry (DEXA) scanning—the gold standard for body composition assessment—researchers found that retatrutide's lean mass loss proportion aligned with other weight loss interventions, including bariatric surgery. Approximately 62-75% of weight loss came from fat mass, with 25-38% from lean mass.

While some lean tissue loss remains inevitable during substantial caloric deficits, retatrutide demonstrated greater reduction of visceral adipose tissue compared to subcutaneous fat. The 12 mg dose achieved mean fat mass reduction of 26.1% over 36 weeks in the diabetic population, with preferential targeting of metabolically active fat depots.

Comparison of Body Composition Changes Across Weight Loss Interventions

Intervention	Total Weight Loss	Fat Mass Loss	Lean Mass Loss	Study Duration
Retatrutide 12mg	24.2-28.7%	~75%	~25%	48-68 weeks
Tirzepatide 15mg	20.2-21.3%	~75%	~25%	72 weeks
Semaglutide 2.4mg	14.9-17.4%	~60%	~40%	68 weeks
Bariatric Surgery	25-32%	~70%	~30%	12 months

For men on TRT, these findings suggest that retatrutide delivers substantial fat loss without disproportionate muscle sacrifice compared to other interventions. However, the absolute amount of lean tissue lost—potentially 15-20 pounds for someone losing 70 pounds total—underscores the critical importance of resistance training and adequate protein intake during treatment.

Side Effect Profile and Tolerability Concerns​

No medication delivering retatrutide's degree of weight loss comes without side effects. Understanding the tolerability profile proves essential for setting realistic expectations and implementing appropriate monitoring protocols.

Gastrointestinal Effects​

Like all incretin-based therapies, retatrutide's most common adverse effects involve the gastrointestinal system. Nausea occurred in approximately 30-40% of participants on higher doses, though intensity typically classified as mild to moderate. Diarrhea, vomiting, and constipation affected 15-25% of participants, with symptoms generally most prominent during dose escalation phases.

The TRIUMPH-4 trial revealed discontinuation rates of 12-18% due to adverse events at the 9-12 mg doses, compared with 4% in the placebo group. Notably, some discontinuations occurred due to 'perceived excessive weight loss'—participants with lower baseline BMI who experienced more rapid weight reduction than desired. Among those with BMI above 35, discontinuation rates dropped to approximately 12%, comparable to rates seen with tirzepatide and semaglutide.

Dysesthesia: A Novel Side Effect​

TRIUMPH-4 identified an unexpected adverse event: dysesthesia, or abnormal tactile sensations, occurred in 8.8% of participants on 9 mg and 20.9% on 12 mg, compared with just 0.7% on placebo. This skin sensitivity manifested as tingling, numbness, or hypersensitivity to touch, typically described as mild and not associated with visible skin changes.

The mechanism remains unclear, though theories include glucagon receptor effects on peripheral nerve function or metabolic changes associated with rapid fat mobilization. Most cases resolved spontaneously or with dose reduction. No participants discontinued specifically due to dysesthesia, suggesting manageable severity despite relatively high prevalence.

Cardiovascular and Metabolic Monitoring​

Mild increases in heart rate occurred at higher doses, averaging 2-4 beats per minute above baseline—consistent with other GLP-1 receptor agonists. This modest elevation typically diminished over time and rarely necessitated intervention. The 2024 FDA removal of the black box cardiovascular warning from testosterone products, following the TRAVERSE trial's demonstration of cardiovascular safety, provides reassurance that combining TRT with retatrutide should not create additive cardiovascular risk for appropriate candidates.

Practical Considerations for Men on TRT​

Integrating retatrutide into a comprehensive TRT optimization protocol requires attention to several key factors that distinguish this population from general obesity cohorts.

Testosterone and GLP-1 Synergy​

Emerging evidence suggests potential synergy between testosterone replacement and GLP-1 receptor agonists for metabolic optimization. A 2025 study presented at the Endocrine Society's ENDO conference found that GLP-1 medications may raise testosterone levels in obese men through weight loss, particularly visceral fat reduction. Among 110 men followed for 18 months on GLP-1 therapy, the proportion with normal-range testosterone increased from 53% to 77% without testosterone supplementation.

For men already on TRT, retatrutide's visceral fat reduction may enhance testosterone's anabolic effects by reducing aromatase activity in adipose tissue and improving insulin sensitivity. This metabolic optimization could translate to better muscle retention during weight loss, though direct studies in TRT populations remain needed.

Resistance Training and Protein Requirements​

Given the substantial lean mass loss that accompanies any significant weight reduction, structured resistance training becomes non-negotiable for men on retatrutide. Current recommendations suggest at least two weekly resistance training sessions targeting all major muscle groups, with progressive overload to stimulate muscle protein synthesis.

Protein requirements during aggressive weight loss likely exceed standard recommendations. Evidence suggests 1.2-1.6 grams per kilogram of body weight daily, distributed across 3-4 meals, optimizes muscle preservation. For a 200-pound man, this translates to roughly 110-145 grams daily—substantially higher than the 0.8 g/kg minimum for weight-stable individuals. The anabolic stimulus from TRT may enhance the muscle-sparing effects of adequate protein intake.

Dosing Protocols and Titration Strategies​

Clinical trials established clear dose-escalation protocols designed to minimize gastrointestinal side effects while optimizing efficacy. Understanding these titration schemes helps set appropriate expectations for treatment timelines.

Standard Escalation Protocol​

TRIUMPH trials initiated treatment at 2 mg weekly, with dose increases every four weeks until reaching the target maintenance dose. For the 12 mg target, the typical progression follows: 2 mg for weeks 1-4, 4 mg for weeks 5-8, 6 mg for weeks 9-12, 9 mg for weeks 13-16, and finally 12 mg from week 17 onward. This gradual escalation, spanning approximately four months, allows the GI system to adapt to increasing medication levels.

ExcelMale community members report variable tolerance to escalation speed. Some individuals, particularly those who experienced significant GI distress on previous GLP-1 medications, benefit from even slower titration—potentially extending the 2 mg phase to 6-8 weeks before advancing. The trade-off involves delayed weight loss but substantially improved treatment adherence.

Real-World Experiences from the ExcelMale Community​

Clinical trial data provides essential efficacy and safety information, but real-world experiences from men on TRT offer invaluable insights into practical implementation, tolerability variations, and quality-of-life impacts.

Positive Outcomes and Unexpected Benefits​

One ExcelMale member reported losing 8 pounds in the first two weeks on 1 mg weekly, experiencing zero gastrointestinal side effects despite previous intolerance to both semaglutide and tirzepatide. After titrating to 2 mg and eventually 3 mg over several weeks, he described return to size 34 pants, decreased wine consumption due to reduced cravings, and resolution of initial fatigue.

Another member's wife achieved 60 pounds of weight loss over 8 months with minimal GI issues, representing approximately 24-25% reduction for someone starting around 240 pounds—consistent with clinical trial outcomes. The couple's experience highlights retatrutide's potential for superior GI tolerability compared to earlier incretin-based medications.

Individual Variability and Side Effects​

Not all experiences prove uniformly positive. One member reported significant anxiety and insomnia at any retatrutide dose, attributing these effects to the glucagon component's metabolic activation. This highlights an important reality: the triple agonist mechanism that creates superior efficacy for most individuals may prove intolerable for a subset of users, particularly those sensitive to sympathomimetic or metabolically activating medications.

Liver Health and Metabolic Disease Applications​

Beyond obesity and diabetes, retatrutide demonstrates remarkable efficacy for metabolic dysfunction-associated steatotic liver disease (MASLD)—a condition affecting an estimated 65% of men with type 2 diabetes and common among those with metabolic syndrome even without overt diabetes.
A 2024 Nature Medicine study evaluated retatrutide in 98 participants with at least 10% liver fat. At 48 weeks, the 12 mg dose achieved 86% mean reduction in hepatic fat content, with 93% of participants normalizing liver fat to below 5%. This profound effect likely reflects multiple mechanisms: weight loss itself reduces hepatic triglyceride accumulation, glucagon receptor activation enhances hepatic fat oxidation, and improved insulin sensitivity decreases de novo lipogenesis.

For men on TRT with elevated liver enzymes or ultrasound evidence of fatty liver, retatrutide may address the underlying metabolic dysfunction more comprehensively than current standard therapies. The glucagon receptor's direct hepatic effects distinguish retatrutide from GLP-1 and GIP agonists, which lack direct hepatic receptor engagement.

Availability, Access, and Cost Considerations​

As of January 2026, retatrutide remains investigational and not FDA-approved. The completion of TRIUMPH Phase 3 trials through 2026, followed by regulatory submission and review, suggests potential approval in late 2026 or 2027. Until FDA approval, retatrutide cannot be legally prescribed or dispensed through conventional pharmaceutical channels in the United States.

ExcelMale community members reporting current retatrutide use appear to be accessing compound pharmacy preparations or international sources. This practice carries significant risks: quality control variability, potential contamination, absence of pharmaceutical-grade assurance, and legal ambiguity. The FDA has specifically warned about counterfeit semaglutide and tirzepatide products; similar concerns will likely extend to retatrutide as interest grows.

Upon FDA approval, cost will represent a substantial barrier for many patients. Tirzepatide carries a list price exceeding $1,000 monthly; retatrutide's pricing will likely match or exceed this given its superior efficacy profile. Insurance coverage patterns remain uncertain, though obesity medication access has improved following Medicare coverage expansion in 2024. Men considering retatrutide should factor potential out-of-pocket costs of $500-1,500 monthly depending on insurance status and manufacturer assistance programs.

Comparing Retatrutide to Alternative Weight Loss Strategies​

For men on TRT evaluating weight loss options, retatrutide exists within a spectrum of interventions ranging from lifestyle modification to bariatric surgery. Understanding relative efficacy, safety profiles, and practical implications helps inform individualized treatment decisions.

Versus Earlier GLP-1 Medications​

Retatrutide's 28.7% weight loss at 68 weeks substantially exceeds semaglutide's 14.9% and tirzepatide's 20.2% at similar durations. This approximate 40% superiority over tirzepatide and 90% advantage over semaglutide translates to meaningful real-world differences: a man losing 60 pounds on retatrutide might have achieved only 40 pounds on tirzepatide or 30 pounds on semaglutide.

However, tolerability profiles matter substantially. Some individuals who cannot tolerate retatrutide due to anxiety, insomnia, or dysesthesia might achieve satisfactory results on tirzepatide or semaglutide with better subjective tolerance. The 'best' medication remains highly individual rather than universally determined by efficacy rankings.

Versus Bariatric Surgery​

Retatrutide's 28.7% weight loss approaches outcomes from sleeve gastrectomy (25-30% at one year) and exceeds gastric banding (15-20%), though remains modestly below Roux-en-Y gastric bypass (30-35%). The critical distinction involves permanence: surgical procedures create anatomical changes producing durable weight loss even after the intensive adjustment period, whereas retatrutide requires indefinite continuation to maintain benefits. Trial data consistently shows weight regain upon medication discontinuation.

Future Directions and Ongoing Research​

Retatrutide's clinical development extends far beyond the obesity indication established in TRIUMPH-4. Eli Lilly has initiated multiple additional Phase 3 trials evaluating retatrutide's efficacy across various obesity-related complications and patient populations.

TRIUMPH-3 evaluates cardiovascular outcomes in individuals with established atherosclerotic disease—a population highly relevant for men on TRT given their elevated baseline cardiovascular risk. Results, expected in 2026, will determine whether retatrutide's profound metabolic improvements translate to reduced major adverse cardiovascular events (MACE) beyond weight loss alone.

Additional ongoing trials examine retatrutide's effects on obstructive sleep apnea, chronic low back pain, and renal outcomes. Perhaps most intriguingly, research into metabolic dysfunction-associated steatohepatitis (MASH) evaluates whether retatrutide's hepatic fat reduction translates to fibrosis regression—a potential breakthrough given the absence of approved MASH therapies.

For men on TRT, dedicated studies examining retatrutide in this population would prove invaluable. Questions about testosterone-retatrutide interactions, muscle preservation strategies, and optimal protein intake requirements remain incompletely answered. The ExcelMale community's evolving experience will continue providing real-world insights as clinical research advances.

Conclusion: A Genuine Advance in Obesity Pharmacotherapy​

Retatrutide represents a substantive advancement in obesity medicine, delivering unprecedented weight loss efficacy while addressing many limitations of earlier incretin-based therapies. The 28.7% average weight reduction observed in TRIUMPH-4—approximately 70 pounds for many men—approaches bariatric surgery outcomes through pharmacological intervention alone.

For men on TRT, retatrutide's profile holds particular appeal: substantial visceral fat reduction, cardiovascular benefit demonstration, reasonable muscle preservation relative to total weight loss, and improved GI tolerability compared to earlier GLP-1 medications in some individuals. The potential synergy between testosterone's anabolic effects and retatrutide's metabolic optimization creates an intriguing foundation for comprehensive body composition improvement.

However, retatrutide should not be viewed as a panacea. Lean tissue loss remains substantial in absolute terms, necessitating dedicated resistance training and protein optimization. Side effects, particularly dysesthesia and potential CNS stimulation, may prove intolerable for some users. Cost and access barriers will limit widespread adoption. Most importantly, long-term data on safety, efficacy maintenance, and cardiovascular outcomes remain forthcoming.

As clinical research progresses through 2026 and regulatory approval approaches, men on TRT considering retatrutide should maintain realistic expectations: this medication offers remarkable efficacy within the context of comprehensive lifestyle optimization, not as a replacement for fundamental metabolic health practices. The integration of proper nutrition, structured training, optimized testosterone management, and evidence-based pharmacotherapy represents the true paradigm for sustainable body composition transformation.

DOWNLOAD RETATRUTIDE SLIDES HERE

Related ExcelMale Forum Discussions​

Explore these community discussions for additional insights:
• Retatrutide - A Game Changer in Obesity Pharmacotherapy – Community members share their real-world experiences with retatrutide, including dosing strategies, side effect management, and weight loss results.

Key References​

1. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2024. https://investor.lilly.com
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://www.nejm.org
3. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. https://www.thelancet.com
4. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048. https://www.nature.com
5. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov
6. Katsi V, Koutsopoulos G, Fragoulis C, et al. Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. https://pmc.ncbi.nlm.nih.gov
7. Walia A. Testosterone Replacement, Where Are We in 2025? Trends Urol Men's Health. 2025. https://onlinelibrary.wiley.com
8. Xiao YJ, Wang YN, Yu LX, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025. https://pmc.ncbi.nlm.nih.gov
9. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(6):2720-2729. https://pubmed.ncbi.nlm.nih.gov
10. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov

Medical Disclaimer​

This article is provided for informational and educational purposes only and does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA. The information presented reflects clinical trial data and early real-world experiences but should not be used as a basis for medical decision-making without consultation with qualified healthcare providers.
Men considering weight loss medications should consult with physicians experienced in obesity medicine and hormone replacement therapy. Individual responses to retatrutide vary substantially, and the medication may not be appropriate for all patients. Always discuss potential risks, benefits, and alternatives with your healthcare provider before initiating any new treatment.

About ExcelMale​

ExcelMale.com is a comprehensive men's health forum with over 24,000 members and a 20+ year archive of discussions on testosterone replacement therapy, hormone optimization, sexual health, and metabolic wellness. Founded by Nelson Vergel, author of Testosterone: A Man's Guide and Beyond Testosterone, the forum provides evidence-based information and peer support for men navigating hormone therapy and overall health optimization.

Visit ExcelMale.com to connect with thousands of men sharing their experiences, access expert insights, and explore comprehensive resources on men's health topics ranging from TRT protocols to nutritional strategies, exercise programming, and emerging pharmacological interventions.

Do the cardiovascular benefits come from the fat loss basically, or what is the mechanism/reason?

 

Good question, and the honest answer is: it's both, with the relative contribution still being worked out.


Fat loss is the dominant driver, but there appear to be at least some direct receptor-mediated effects running in parallel.


What's clearly downstream of fat loss:

• Blood pressure reduction (the 14 mmHg systolic drop in TRIUMPH-4 tracks closely with weight loss magnitude)
• Triglyceride and LDL reductions - largely metabolic improvements from losing visceral fat and reversing insulin resistance
• Reduced systemic inflammation (hs-CRP dropping) - visceral adipose tissue is a major cytokine factory, and clearing it reduces inflammatory burden
• Improved insulin sensitivity - again, mostly a consequence of less visceral fat compressing hepatic and peripheral glucose metabolism

What may be more direct:

• The glucagon receptor activation drives hepatic fat oxidation independently of overall caloric deficit. This is meaningful cardiovascularly because fatty liver strongly predicts cardiovascular risk, and retatrutide clears it faster and more completely than the weight loss alone would explain. The 82-86% liver fat reduction outpaces what simple caloric restriction at equivalent weight loss achieves.
• GLP-1 receptors exist in cardiac tissue and endothelium, and GLP-1 agonists have shown some cardioprotective signaling in animal models and mechanistic studies - anti-inflammatory effects, improved endothelial function, possible direct myocardial effects. Whether this translates meaningfully in humans independent of weight loss is contested. The SUSTAIN and LEADER trials with semaglutide showed cardiovascular benefit, but disentangling weight loss from direct receptor action was never fully resolved.
• GIP receptors are also present in cardiac tissue, though what that means clinically is still unclear.

The honest caveat: This is exactly what the ongoing TRIUMPH-Outcomes trial (10,000 participants) is designed to answer - whether retatrutide produces cardiovascular benefit beyond what the weight loss alone would predict. That trial is what the FDA will want to see before approving retatrutide for cardiovascular indications the way semaglutide got its separate cardiovascular label.


The working clinical assumption right now is that most of the CV benefit is weight-mediated, with glucagon receptor-driven liver fat clearance as an additional independent contributor - but the direct cardiac receptor signaling remains mechanistically plausible and not yet proven at scale.

 

Ran retatrutide for about 16 weeks earlier this year after bouncing between sema and tirze. Honestly? Wish I'd started here. The appetite suppression hits different when you've got all three pathways going—GLP-1, GIP, *and* glucagon. I wasn't just less hungry; the constant food noise in my head went basically silent. You know, that 3pm "what's in the fridge" mental loop? Gone.

Body recomp showed fast. Scale moved, sure, but shoulders popped more, waist tightened up within a month. Biggest surprise was alcohol—used to crush 4-5 beers on weekends without thinking. Just... stopped wanting it. Didn't white-knuckle or plan for it. The craving evaporated like everything else.

Sides were milder than tirze for me. Some nausea first two weeks at 4mg, backed down to 2mg, titrated slower. No gallbladder issues, no crazy fatigue.

Only downside? Coming off, that noise tries creeping back. Learned I actually have to eat intentionally now. Weird problem to have.

 

Did you end up pulling the trigger on that Janoshik test? Curious how the turnaround was since I've heard mixed things lately.

Food noise going quiet was the biggest difference for me when I switched over—like not just muted but *gone*. On tirze I'd still catch myself thinking about what was in the fridge at 10pm. With reta that whole mental loop just... stopped. Took about ten days to really feel it.

Your titration looks conservative but smart, especially coming from 10mg tirze. I'd maybe stretch that 0.25mg out to three weeks if sides hit, since the build-up is real. The twice-weekly pinning helped me avoid the crash I'd get with daily peptides, and I found morning doses way easier on my gut than evening.

Stability-wise I never kept reconstituted vials past 30 days, but at your dosing you'll burn through them faster than that anyway. Just watch for anything precipitating out—cloudy or stringy means it's toast. Keep us posted on that COA when it comes back.